#Retatrutide,
An experimental GLP-1 drug pushes the limits of weight loss.

There are risks.

Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity to shed, on average, 28 percent of their body weight
— a substantial step up in potency from the existing crop of GLP-1 medicines.

But that breakthrough also is prompting some doctors to urge caution.

In interviews, doctors warned that using a drug to shrink your body that much will require close medical management
And — much more than the level of monitoring many people are now getting when taking drugs like Ozempic, Wegovy and Zepbound.

https://www.washingtonpost.com/health/2026/05/29/when-is-glp-1-drug-too-potent/

An experimental GLP-1 pushes the limits of weight loss. There are risks.

Eli Lilly is developing the the most powerful GLP-1 drug yet. But how much weight loss is too much?

The Washington Post

Trenta chili persi in due anni, il 28% del peso corporeo: i numeri (in fase 3) che Eli Lilly ha tirato fuori per retatrutide, il suo agonista triplo, sono i più alti mai visti da un farmaco dimagrante, e cominciano a sfiorare territori che finora erano roba da chirurgia.

La "guerra" farmaceutica tra farmaci dimagranti e solo all'inizio, e la posta in gioco è altissima. Ne faremo le spese (e/o ne beneficieremo) noi.

https://www.futuroprossimo.it/2026/05/retatrutide-numeri-da-record-per-la-terza-fase-dellanti-ozempic

#futuroprossimo #retatrutide #obesità

The Biochemical Beauty of Retatrutide: How GLP-1s Actually Work

On some level, calories in calories out has to be true. But these variables are not independent. Bodies respond to exercise by getting hungry and to calorie deficit by getting tired. Even absent th…

Aceso Under Glass

Update: New Options for Weight Loss

The landscape of metabolic medicine is shifting beneath our feet. For the last few years, the conversation has been dominated by weekly injections like #Zepbound (#tirzepatide), #Wegovy (#semaglutide), #Foundayo (#orforglipron) and #retatrutide.

https://bit.ly/4sbhJVl
#obesity #WeightLoss

Are You Still Natural If You Use Peptides? Retatrutide, BPC-157, & TB-500 Explained | Fit Savanna

Research peptides like retatrutide, BPC-157, and TB-500 are experimental compounds with no quality control, no medical oversight, and significant safety concerns. For competitive athletes, using them means you're no longer natural according to sport regulations.

Fit Savanna

Well this is a disturbing development, are the drugs we use what they seem?
I've seen how regulation has collapsed in America, I hope we're not following down that same Libertarian shit show?

https://www.theguardian.com/world/2025/oct/24/northampton-factory-making-counterfeit-weight-loss-jabs-raided

#Drugs #Medicines #UKCrime #retatrutide #tirzepatide

More than £250,000 of counterfeit weight-loss jab products seized in factory raid

Unlicensed and potentially deadly products seized in Northampton in crackdown on illegal trade

The Guardian
@miffyhelen I'm type 2 diabetic AND an inpatient pharmacist. Ever since I started taking #incretin drugs — first #Bydureon (#exenatide), then #Ozempic (#semaglutide), and most recently #Mounjaro (#tirzepatide) — it has transformed my experience of exercise. Before, I never understood how anyone could enjoy exercise. I suspect another diabetes drug of a different class, good old #metformin, is helping too. #Mounjaro, especially, has made a world of difference. If you're not diabetic, #tirzepatide is also available as a weight-loss drug under a different name (#Zepbound). And another #incretin drug, not approved yet, is on the horizon: #retatrutide. From everything I've read about it, it should be the best of all.

Watch out, Novo Nordisk. Lilly’s #retatrutide, a so-called triple G, has bettered not only Novo’s #Wegovy but Lilly’s own #Mounjaro when data from three different obesity trials are compared. The project allowed obese patients to lose nearly a quarter of their bodyweight after around a year’s treatment.

The downside was, as so often with incretins, side-effects, with 16% of patients in the high-dose group suffering so badly they withdrew from treatment.
#obesity
https://www.evaluate.com/node/18974/pdf

Wow!

Phase 2 data show 24% weight loss with triple-agonist retatrutide!

Key takeaways:

#Retatrutide, a triple-hormone agonist, was associated with 24.2% weight loss at the highest dose for people with #obesity.

The #GLP-1/#GIP/#glucagon agonist also reduced #HbA1c and body weight in type 2 #diabetes.

#lilly #mounjaro #ozempic #wegovy #weightloss
https://www.healio.com/news/endocrinology/20230626/this-raises-the-bar-phase-2-data-show-24-weight-loss-with-tripleagonist-retatrutide